Memory T Cell Dynamics in the Lung during Influenza Virus Infection

Angela Pizzolla and Linda M. Wakim
J Immunol January 15, 2019, 202 (2) 374-381; DOI: https://doi.org/10.4049/jimmunol.1800979

Abstract

Influenza A virus is highly contagious, infecting 5–15% of the global population every year. It causes significant morbidity and mortality, particularly among immunocompromised and at-risk individuals. Influenza virus is constantly evolving, undergoing continuous, rapid, and unpredictable mutation, giving rise to novel viruses that can escape the humoral immunity generated by current influenza virus vaccines. Growing evidence indicates that influenza-specific T cells resident along the respiratory tract are highly effective at providing potent and rapid protection against this inhaled pathogen. As these T cells recognize fragments of the virus that are highly conserved and less prone to mutation, they have the potential to provide cross-strain protection against a wide breadth of influenza viruses, including newly emerging strains. In this review, we will discuss how influenza-specific memory T cells in the lung are established and maintained and how we can harness this knowledge to design broadly protective influenza A virus vaccines.

Introduction

Influenza A virus (IAV) is an ssRNA virus that infects the respiratory tract. This virus causes the “flu,” a malaise with local inflammation and systemic symptoms that can vary in severity from a runny nose and sore throat to viral pneumonia. Annually, influenza virus infects 3–5 million people worldwide, with an estimated mortality rate of 300,000–600,000 people (1). In addition to the loss of life, annual influenza outbreaks are a major burden on global economies because of the direct cost of healthcare as well as lost productivity due to illness. Currently, the best protection against IAV is annual immunization with an i.m. trivalent or quadrivalent vaccine, which induces neutralizing Abs to the viral surface glycoproteins (hemagglutinin [HA] and neuraminidase [NA]). However, as these glycoproteins mutate frequently, it is necessary to reformulate and administer vaccines annually to maintain protective immunity (2). Current vaccines also offer no protection during a pandemic outbreak, in which the emergence of novel viruses from animal reservoirs spreads rapidly worldwide, having a devastating impact on global health.

In contrast to the current vaccines, natural infection with a strain of IAV is able to protect an individual against a secondary infection with a heterologous IAV strain, displaying different HA and NA molecules (3). The T cell compartment is responsible for this heterologous protection (4, 5). This is because T cells recognize internal and more conserved parts of the influenza virus that are far less prone to mutation (6–10). Experiments in animal models clearly highlight the importance of T cell immunity in the protection against influenza virus. The transfer of Ag-experienced IAV-specific CD8+ and CD4+ T cells into naive recipient mice can confer protection against heterologous viruses (11–13). Furthermore, depleting mice that have recovered from a prior IAV infection of memory T cells renders these animals more susceptible to secondary infection (14, 15). Consistent with these animal studies, recently, it was shown that IAV-specific CD4+ and CD8+ memory T cells in humans are also cross-reactive (16), and the presence of IAV-specific CD4+ and CD8+ T cells correlated with better protection from subsequent infection (17, 18). Not all subsets of memory T cells evoked during pulmonary IAV infection are equally protective, with the memory T cells that remain resident in the lung providing the most potent protection against a second heterologous lung IAV infection (15, 19–23). A vaccine that deposits IAV-specific T cells along the respiratory tract has the potential to provide long-lasting immunity against both seasonal circulating influenza strains as well as newly emerging pandemic viruses. Defining parameters that promote influenza-specific lung-resident memory T cell formation and maintenance is a critical step toward the development of such a vaccine.

In this review, we will focus on IAV-specific CD4+ and CD8+ memory T cells that are resident within the lung and will discuss factors influencing their induction, function, and persistence. In addition, we will review exciting new experimental vaccination protocols that are being developed to specifically evoke memory T cells in the lung, which if proven effective, are likely to save lives, reduce health care costs, and reduce lost economic productivity.

Priming: the activation of the IAV-specific T cell response

IAV infection and replication in airway epithelial cells induces the production of cytokines and chemokines. Although these inflammatory agents drive the recruitment of innate immune cells into the lung (neutrophils and monocytes), which are essential to dampen the early stages of IAV infection [reviewed in Ref. (24)], ultimately, it is the adaptive immune response that is responsible for ridding the body of this virus infection (25).

Respiratory dendritic cells (DCs) play an important role in orchestrating this adaptive immune response. In mice, lung conventional DCs can be subdivided into two subsets termed CD103+ DCs and CD11b+ DCs (26). IAV infection of the airways induces the maturation of these respiratory DCs, which migrate from the lung to the mediastinal lymph nodes (LNs) carrying IAV Ags, which are necessary to initiate an IAV-specific T cell response (27). Both DC subsets are important in the development of an optimal T cell response; the CD103+ DCs subset is essential and most efficient at priming of IAV-specific CD4+ and CD8+ T cells within the first few days postinfection, whereas the CD11b+ DC subset is the dominant APC at later time points (28). In addition to lung-migratory DCs, LN-resident DCs, specifically the CD8α+ XCR1+ subset, are also involved in priming naive CD8+ T cells via cross-presentation following IAV infection (29–32).

Upon reaching these lymphoid organs, DCs develop into a mature state, which is characterized by high levels of expression of MHC and T cell costimulatory molecules (CD80/CD86/CD70) and the ability to present Ag captured in the periphery to naive T cells. Naive T cells encounter their cognate Ag presented by activated DCs loaded on MHC class I, in the case of CD8+ T cells, or MHC class II (MHC-II) for CD4+ T cells. The T cells activated following IAV infection recognize viral Ags derived from several internal and external viral proteins. In both mice and humans, the CD8+ T cell response is focused toward internal proteins (nucleoprotein [NP] and polymerases [PA and PB1] and matrix protein M1) (6, 33, 34). In contrast, the CD4+ T cell response is directed toward both external proteins, HA and NA, as well as internal proteins, NP, PA, PB1 (35–39). As T cells recognize peptides derived from more conserved influenza virus proteins (8, 39–42), they have the potential to mediate cross-reactive immunity toward distinct IAV strains.

Following their activation within lymphoid organs, IAV-specific effector CD8+ and CD4+ T cells upregulate adhesion molecules and chemokine receptors that guide their migration to the infected respiratory tract. Activation by lung-migratory DCs drives IAV-specific CD4+ T cells to upregulate expression of CCR4 (43), and this facilitates homing into the infected lung tissue, which expresses elevated levels of MIP-1α, MCP-1, and CCL5 (RANTES) (44). IAV-specific effector CD8+ T cells upregulate CXCR4 and are guided by a trail of CXCL12 left behind by neutrophils, which infiltrate the IAV-infected respiratory tract (45). Once in the inflamed IAV-infected lung tissue, effector CD4+ and CD8+ T cells need to see their cognate Ag again, either on infected cells or presented on lung DCs, to gain full effector function, become cytotoxic, as well as produce proinflammatory cytokines (46, 47). This secondary antigenic interaction is directed by the chemokine CXCL10, which recruits CXCR3+ effector T cells to Ag depots (48).

Within the IAV-infected lung tissue, CD4+ and CD8+ T cells produce both proinflammatory cytokines (TNF-α, IFN-γ, and IL-2), as well as anti-inflammatory cytokines (such as IL-10) (49, 50), which allow these cells to clear the virus infection and moderate tissue damage. Although effector CD4+ T cells after IAV infection predominately adopt a Th1 phenotype, in the absence of IL-10, these cells can be persuaded to differentiate into IL-17–producing Th17 cells, which are also protective during a high-dose influenza virus challenge (51). Additionally, CD4+ T cells can also differentiate into T follicular helper cells (Tfh), which are pivotal for the activation of B cells, and cytotoxic CD4+ T cells, which can kill viral-infected cells by direct cytotoxicity. CD4+ T cell differentiation is directed by several factors, including cytokine environment (i.e., IL-21 sways the cells toward a Tfh phenotype, whereas IL-2 promotes differentiation of cytotoxic CD4+ T cells) and TCR–MHC-II affinity (i.e., high–Ag affinity and TCR signal strength favors Th1 differentiation) (52, 53). IAV-specific cytotoxic CD4+ T cells in the lung can kill via a perforin-dependent MHC-II– specific mechanism (49, 54). These cells express granzyme B and IFN-γ and are characterized by the expression of NK markers like NKG2C/E and CRTAM (MHC class I–restricted T cell–associated molecule) (49, 55, 56). These killer CD4+ T cells have also been identified in humans after IAV challenge (17).

The majority of effector CD8+ T cells within IAV-infected lungs produce proinflammatory cytokines (TNF-α, IFN-γ, and IL-2); however, a small proportion produce IL-4 and IL-5 or IL-17, which are classically defined as Th2 and Th17 cytokines (57, 58). Although cytokine production by effector CD8+ T cells aids in IAV control, the main function of these cells during IAV infection is to kill virus-infected cells (59). This cytotoxicity is mediated by granzymes and proapoptotic proteases, which penetrate the target cells through perforin pores (60, 61) and by the interaction of the cell surface death receptors FAS-FASL and TRAIL-DR5 (61, 62). CD8+ T cell function is regulated by TCR signal strength, with cytolytic activity being triggered by weak TCR signaling and cytokine production being favored following stronger TCR signaling interactions (63–65).

Development of IAV-specific memory T cell responses

Following the clearance of IAV from the lung, the vast majority of effector CD4+ and CD8+ T cells perish, leaving behind a small pool of long-lived, Ag-experienced memory T cells. Whether an effector T cell transitions into a memory cell is influenced by early events occurring during T cell priming (66), which see KLRG1lo CD127(IL-7Ra)lo effector cells segregating into either terminally differentiated short-lived effector T cells (KLRG1hi and CD127lo) or memory precursors T cells (KLRG1lo CD127hi) (67). This differentiation process is driven by a panel of transcription factors; effector T cells highly express T-bet, ID2, Blimp-1, and STAT4, whereas memory precursor effector T cells express Eomes, ID3, Bcl-6, STAT3, Foxo1 and Tcf1, Hobit, and Runx3 (68, 69).

Other signaling events, including TCR stimulation, cytokine/chemokine exposure, and costimulatory molecule signaling, all impact on the ability of an effector T cell to transition into a long-lived memory cell. In particular, the inflammatory environment within the host over the course of an infection heavily influences effector T cell survival and memory T cell development (70). High levels of IFN-γ in the lung during an IAV infection help to dampen inflammation and promote T cell contraction (71, 72), and blocking this cytokine during IAV infection increased the accumulation of effector and memory CD8+ T cells in the lung, which leads to an accelerated clearance of virus from this tissue (72). The inflammatory milieu during the later stages of IAV infection favors memory T cells differentiation (73). Consistent with this, when naive CD4+ T cells were transferred into an IAV-infected mouse during the early stages of infection, these cells developed into both effector and memory T cells; however, if the transfer was postponed until the later stages of infection, naive T cells preferentially differentiated into memory cells (74).

Optimal transition of effector CD4+ and CD8+ T cells into long-lived memory cells requires a secondary conditioning event in which these cells see their cognate Ag and receive costimulatory signaling from DCs (75). Costimulation, in the form of CD27–CD70 interaction, TCR–MHC-II ligation, and IL-2 signaling is required 5–7 d after priming of CD4+ T cells for optimal CD4+ T cell memory development (76). Similarly, CD8+ T cells require costimulatory signaling from CD27, 4-1BB, and OX40, to promote their survival and differentiation into quality memory cells capable of robust secondary expansion (77, 78). CD4+ and CD8+ memory T cells require IL-7 and IL-15 for their long-term survival and renewal (79–82). Both IL-15 and IL-7 influence T cell metabolism by promoting fatty acids oxidation, the main source of energy for memory cells, via increasing storage of triglyceride (83) or mitochondrial biogenesis (84).

Both memory CD4+ and CD8+ T cells are able to protect mice from a lethal IAV infection in the absence of any other immune cell population (14, 23, 85), and the size of the memory T cell compartment is a good correlate of protection against a secondary heterologous infection (86, 87). In humans, survival from a new influenza strain depends on the presence of memory CD8+ T cells (17, 18), and in a rechallenge study, the numbers of CD4+ T cells directed against internal proteins correlated with lower viral titers and weaker symptoms (17).

Subsets of memory T cells.

Memory CD4+ and CD8+ T cells can be subdivided into three subsets termed central memory, effector memory, and tissue-resident memory T cells (Trm). These cells reside in different anatomical locations and differ both phenotypically and functionally. Central memory T cells (Tcm) express high levels of CD62L and CCR7 and are found in the spleen, LNs, and blood. Effector memory T cells (Tem) do not express CD62L or CCR7, and in addition to being present in the spleen, lymphoid organs, and circulation, can also traffic through peripheral tissues (88–90). Trm represent a self-sustaining, nonmigratory population of memory T cells that are deposited within peripheral tissues, commonly at sites of prior infection (91).

Although both CD4+ and CD8+ Tcm and Tem are capable of producing cytokines upon antigenic stimulation, can proliferate and swiftly migrate into the lung following IAV reinfection (90), a process dependent on their expression of CCR5 (92), it is the Trm subset located along the respiratory tract that provides a frontline defense, rapidly decreasing viral titers and increasing survival rates following a secondary heterologous IAV infection (15, 20, 21). Trm located along the respiratory tract are indispensable for optimal cross-protection against heterologous pulmonary influenza virus infection (20, 93).

Development of Trm in the lung.

Following IAV infection, CD4+ and CD8+ Trm are found in the lung parenchyma, airways, and nasal tissue (15, 20, 22, 94). Lung Trm, similar to Trm characterized in other tissues, are a self-sustaining population that are maintained with minimal need for replenishment by the circulating memory T cell pool (19, 20, 95–97). In the lung, CD4+ and CD8+ Trm congregate either within or around inducible bronchial-associated lymphoid tissue, respectively, and are also enriched in areas where the lung tissue has been remodeled postinfection-associated injury (19, 98, 99). Trm express a variety of adhesion molecules and proteins that facilitate their long-term retention and survival in the lung (19) (Fig. 1). Both CD4+ and CD8+ Trm subsets express CD49a, which complexes with CD29 to form the dimer VLA-1, which binds collagen IV and collagen I and secures these cells in the airways (93, 98, 100). A significant proportion of lung Trm (50–70%) also express CD69 (20, 22), which limits the egress of the cells into the blood stream by antagonizing S1P1 signaling (101). The integrin CD103 is expressed on a proportion of CD69+ CD8+ lung Trm; however, it is absent on the CD4+ lung Trm pool (22, 102). CD103 binds e-cadherin, a junction protein expressed on epithelial cells, which facilitates the retention of the cells within the lung (102–104). Although, CD4+ Trm constitutively express CD11a (22), a component of LFA-1 and ligand of ICAM-1, CD8+ Trm only transiently express this integrin, and as such, the expression of CD11a on CD8+ Trm is commonly used to distinguish recently recruited cells from long-term residents (19, 97). IAV-specific CD4+ and CD8+ Trm have also been identified and characterized in human lung tissue. These cells express the memory marker CD45RO, tissue retention markers CD69, CD49a, and CD103, chemokine receptors CXCR3, 4, and 6 (105–107), and can rapidly produce an array of cytokines (105–107) following TCR stimulation because of their constitutive expression of deployment-ready mRNA encoding effector molecules (108, 109).

FIGURE 1.
FIGURE 1.

The developmental requirements of IAV-specific lung Trm. IAV-specific effector T cells undergo local conditioning and develop into Trm within the influenza virus–infected lung. Exposure to locally produced IFN-γ, TGF-β, IL-15, and cognate Ag recognition promotes the development of lung Trm, which express a key set of transcription factors that drive the upregulation of proteins that facilitate tissue retention and survival and downregulation of proteins that favor T cell egress.

Studies in animal models have defined key developmental requirements of lung Trm and identified factors within the lung microenvironment that promote Trm differentiation and maintenance. Optimal development of influenza virus–specific CD8+ Trm in the lung requires the following: 1) local cognate Ag recognition in the tissue (15, 20, 110), 2) exposure to locally produced TGF-β (99, 102, 103), and 3) the presence of IFN-γ–secreting CD4+ T cells (111) (Fig. 1). Because Trm development in the lung is driven by local cognate Ag recognition, changes in epitope availability over the course of a virus infection impacts the selection of different specificities of T cells into the Trm pool (15, 19, 99). As such, the immunodominance hierarchy within the influenza-specific lung Trm compartment does not reflect that of the circulating memory T cell pool.

Once formed, continued exposure to IL-15, which is produced by macrophages and DCs in the lamina propria of the lung, is necessary for the long-term survival of CD8+ CD103+ Trm (112). In addition, lung Trm retain expression of the IFN-induced transmembrane protein IFITM3, which is a potent antiviral protein that confers broad antiviral resistance (113) and allows these cells to withstand viral infection and better survive within the microenvironment of the lung (113).

Trm have a unique molecular signature that is regulated by a key set of transcription factors. Trm transcriptional profile is characterized by the downregulation of the T-box transcription factors T-bet and Eomes (112, 114), which makes the cells responsive to TGF-β signaling and promotes expression of the IL-15R, which is important for cell survival (112). In addition, exposure of Trm during their development to TGF-β, IL-33, or TNF-α drives the downregulation of the transcription factor KLF2 and its target S1P1R, which limits tissue egress (115). Elevated expression of the transcription factor Runx3 in Trm drives the expression of tissue retention markers CD69 and CD103 (116), whereas elevated expression of the transcription factors Blimp-1 and Hobit also drive the downregulation of molecules associated with T cell egress (117). Although the core transcriptional profile of Trm has been unraveled through extensive interrogation of Trm isolated from mouse tissue, recently it has been shown that CD4+ and CD8+ CD69+ Trm isolated from human tissue exhibit a similar molecular signature and transcriptional program (108, 109, 118).

Fading memory T cells in the lung: “Those who cannot remember the past are condemned to repeat it.”—G. Santayana

Although IAV-specific Trm in the lung provide potent protection against heterosubtypic influenza challenge (21, 119), this protection is transient. Trm in the lung and airways, unlike populations in the skin (96, 120), nasal tissue (15), and intestinal mucosae (121, 122), undergo attrition (14, 20, 93) as a result of increased apoptosis (96). In mice, heterosubtypic immunity to influenza virus wanes 6 to 7 mo after the primary infection despite the fact that a stable and sizable population of IAV-specific CD8+ Tem and Tcm persist within the circulation (123). This loss of protection tightly correlated with a loss of IAV-specific CD8+ T cells in the airways and lung (15, 20, 96, 124). Whereas CD4+ T cells in the lung parenchyma decay less rapidly (19), possibly because of their localization within the inducible bronchial-associated lymphoid tissue, which is perhaps an environment more favorable for cell survival, airway and lung CD8+ Trm undergo an aggressive decay with an estimated t1/2 of just 2 wk (97). Although persistence of residual cognate Ag within the lung (102) and boosting the circulating pool of Tem (96) can extend the longevity of lung CD8+CD103+ Trm, ultimately these cells are lost.

Why lung Trm decay is unclear; however, their fate is likely to be heavily influenced by the microenvironment of the lung. It is possible that the abundance of oxygen in the lung environment is not conducive for the long-term survival of lung CD4+ and CD8+ memory T cells. Indeed, blocking the oxygen-sensing capacity of T cells does increase their functionality in a lung cancer model (125). Furthermore, airway CD8+ Trms over time lose expression of IL-7Ra and IL-15R, becoming less responsive to the prosurvival cytokines IL-7 and IL-15, which could be another mechanism underlying the loss of this population of memory T cells (126).

The key to protective pulmonary immunity to IAV is the presence of IAV-specific lung Trm (20). A vaccine that deposits IAV-specific Trm in the lung has the potential to provide long lasting immunity against this respiratory pathogen. Defining parameters that not only promote IAV-specific lung Trm formation but also support their long-term persistence is an important step toward the development of an effective vaccine.

Vaccination strategies that evoke IAV-specific lung Trm

An IAV vaccine that evokes T cell immunity, directed at internal and highly conserved components of IAV, has the potential to provide long-term, cross-strain protection against both seasonal and emerging pandemic influenza strains (127). Influenza vaccines currently in use do not evoke robust T cell immunity but rather rely on the humoral arm of the immune system to confer protection. The injectable IAV vaccine, which is composed of inactivated IAV virions, boosts Tfh and B cell responses but does not evoke an IAV-specific CD8+ T cell response in humans (128). Although the intranasal IAV vaccine, an attenuated influenza virus engineered to replicate only at the lower temperatures (< 33°C) of the upper respiratory tract, should stimulate both humoral and cellular arms of the immune system, the T cell responses evoked by this vaccine are highly variable (129). Vaccine candidates that specifically evoke IAV-specific T cell immunity are in development. Vaccines that combine CD4+ and CD8+ T cell epitopes from M1 and NP–IAV proteins that have been integrated into an artificial virus (MVA-NP+M1) or synthesized as synthetic polypeptides (Flu-v, FP-0.01, and Multimeric-001), have been tested in humans and can evoke IAV-specific T cell immunity (130–132). Furthermore, the MVA-NP+M1 vaccine could decrease viral shedding and symptoms in a human study in which volunteers were vaccinated and then challenged with an IAV strain for which they had no prior humoral immunity (131). An effective IAV T cell–based vaccine will not only have to elicit a good quantity memory T cell response but also will need to ensure the memory T cell population is deposited in the right location.

Because the demonstration that lung CD8+ Trm are indispensable for optimal cross-protection against pulmonary influenza virus infection, considerable efforts have been made to develop vaccination regimes that specifically evoke this memory T cell population. As the optimal development of respiratory tract Trm requires local cognate Ag recognition, any effective vaccine intended to elicit respiratory tract Trm must deliver the vaccine Ag intranasally into the airways. Studies in animal models have shown that intranasal immunization with influenza peptide/protein alone (98, 133–135) or loaded onto DCs (15) or coupled onto mAbs that target Ag to respiratory DCs (119) are able to successfully generate lung CD8+ Trm that are highly protective against influenza virus challenge. In addition, the intranasal delivery of a nonreplicative influenza virus into the airways or pulmonary vaccination with an adenoviral vector–expressing IAV Ags could also deposit high numbers of influenza-specific lung Trm (21, 136). Furthermore, animal studies show that the intranasal IAV vaccine but not the inactivated IAV virion can evoke lung Trm that are highly protective against influenza challenge (21). Whether these vaccination protocols can evoke IAV-specific lung Trm in humans, which, unlike laboratory mice, have a diverse immunological backdrop to this pathogen, a consequence of prior exposure or vaccination, remains to be determined.

A major obstacle for the development of an intranasal vaccine that evokes lung Trm is that vaccine delivery into the lower airways presents a risk. The lung is a sensitive environment; excessive inflammation elicited by the pulmonary administration of vaccines or inflammatory agents could damage the lung tissue, a situation that could have a negative impact on respiratory health (137).

Conclusions

Trm in the lung provide a frontline defense against influenza virus infection. Although able to provide cross-strain protection against a wide breadth of influenza viruses, including newly emerging strains, this protection, because of the short t1/2 of these cells, is only transient. If lung Trm are to be harnessed in vaccines that protect against influenza virus, then finding ways to safely induce these cells and improve their stability is a challenge that will need to be addressed in coming years.

Disclosures

The authors have no financial conflicts of interest.

Footnotes

  • Abbreviations used in this article:

    DC
    dendritic cell
    HA
    hemagglutinin
    IAV
    influenza A virus
    LN
    lymph node
    MHC-II
    MHC class II
    NA
    neuraminidase
    NP
    nucleoprotein
    Tcm
    central memory T cell
    Tem
    effector memory T cell
    Tfh
    T follicular helper cell
    Trm
    tissue-resident memory T cell.

  • Received July 13, 2018.
  • Accepted September 8, 2018.

References

  1. ↵
    1. World Health Organization
    . 2018. Influenza Fact Sheet. Available at: http://www.who.int/mediacentre/factsheets/fs211/en/. Accessed: April 4, 2018.
  2. ↵
    1. Westgeest, K. B.,
    2. C. A. Russell,
    3. X. Lin,
    4. M. I. Spronken,
    5. T. M. Bestebroer,
    6. J. Bahl,
    7. R. van Beek,
    8. E. Skepner,
    9. R. A. Halpin,
    10. J. C. de Jong, et al
    . 2014. Genomewide analysis of reassortment and evolution of human influenza A(H3N2) viruses circulating between 1968 and 2011. J. Virol. 88: 2844–2857.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Schulman, J. L.,
    2. E. D. Kilbourne
    . 1965. Induction of partial specific heterotypic immunity in mice by a single infection with influenza a virus. J. Bacteriol. 89: 170–174.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Yap, K. L.,
    2. G. L. Ada
    . 1978. The recovery of mice from influenza A virus infection: adoptive transfer of immunity with influenza virus-specific cytotoxic T lymphocytes recognizing a common virion antigen. Scand. J. Immunol. 8: 413–420.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Effros, R. B.,
    2. P. C. Doherty,
    3. W. Gerhard,
    4. J. Bennink
    . 1977. Generation of both cross-reactive and virus-specific T-cell populations after immunization with serologically distinct influenza A viruses. J. Exp. Med. 145: 557–568.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Belz, G. T.,
    2. W. Xie,
    3. J. D. Altman,
    4. P. C. Doherty
    . 2000. A previously unrecognized H-2D(b)-restricted peptide prominent in the primary influenza A virus-specific CD8(+) T-cell response is much less apparent following secondary challenge. J. Virol. 74: 3486–3493.
    OpenUrlAbstract/FREE Full Text
    1. Bennink, J. R.,
    2. J. W. Yewdell,
    3. G. L. Smith,
    4. B. Moss
    . 1987. Anti-influenza virus cytotoxic T lymphocytes recognize the three viral polymerases and a nonstructural protein: responsiveness to individual viral antigens is major histocompatibility complex controlled. J. Virol. 61: 1098–1102.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Gotch, F.,
    2. A. McMichael,
    3. G. Smith,
    4. B. Moss
    . 1987. Identification of viral molecules recognized by influenza-specific human cytotoxic T lymphocytes. J. Exp. Med. 165: 408–416.
    OpenUrlAbstract/FREE Full Text
    1. Scherle, P. A.,
    2. W. Gerhard
    . 1986. Functional analysis of influenza-specific helper T cell clones in vivo. T cells specific for internal viral proteins provide cognate help for B cell responses to hemagglutinin. J. Exp. Med. 164: 1114–1128.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Yewdell, J. W.,
    2. J. R. Bennink,
    3. G. L. Smith,
    4. B. Moss
    . 1985. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA 82: 1785–1789.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Scherle, P. A.,
    2. G. Palladino,
    3. W. Gerhard
    . 1992. Mice can recover from pulmonary influenza virus infection in the absence of class I-restricted cytotoxic T cells. J. Immunol. 148: 212–217.
    OpenUrlAbstract
    1. Lightman, S.,
    2. S. Cobbold,
    3. H. Waldmann,
    4. B. A. Askonas
    . 1987. Do L3T4+ T cells act as effector cells in protection against influenza virus infection. Immunology 62: 139–144.
    OpenUrlPubMed
  13. ↵
    1. Alam, S.,
    2. A. J. Sant
    . 2011. Infection with seasonal influenza virus elicits CD4 T cells specific for genetically conserved epitopes that can be rapidly mobilized for protective immunity to pandemic H1N1 influenza virus. J. Virol. 85: 13310–13321.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Liang, S.,
    2. K. Mozdzanowska,
    3. G. Palladino,
    4. W. Gerhard
    . 1994. Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. J. Immunol. 152: 1653–1661.
    OpenUrlAbstract
  15. ↵
    1. Pizzolla, A.,
    2. T. H. O. Nguyen,
    3. J. M. Smith,
    4. A. G. Brooks,
    5. K. Kedzieska,
    6. W. R. Heath,
    7. P. C. Reading,
    8. L. M. Wakim
    . 2017. Resident memory CD8+ T cells in the upper respiratory tract prevent pulmonary influenza virus infection. Sci. Immunol. DOI: 10.1126/sciimmunol.aam6970.
  16. ↵
    1. Lee, L. Y.,
    2. L. A. Ha,
    3. C. Simmons,
    4. M. D. de Jong,
    5. N. V. Chau,
    6. R. Schumacher,
    7. Y. C. Peng,
    8. A. J. McMichael,
    9. J. J. Farrar,
    10. G. L. Smith, et al
    . 2008. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J. Clin. Invest. 118: 3478–3490.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Wilkinson, T. M.,
    2. C. K. Li,
    3. C. S. Chui,
    4. A. K. Huang,
    5. M. Perkins,
    6. J. C. Liebner,
    7. R. Lambkin-Williams,
    8. A. Gilbert,
    9. J. Oxford,
    10. B. Nicholas, et al
    . 2012. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat. Med. 18: 274–280.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Wang, Z.,
    2. Y. Wan,
    3. C. Qiu,
    4. S. Quiñones-Parra,
    5. Z. Zhu,
    6. L. Loh,
    7. D. Tian,
    8. Y. Ren,
    9. Y. Hu,
    10. X. Zhang, et al
    . 2015. Recovery from severe H7N9 disease is associated with diverse response mechanisms dominated by CD8+ T cells. Nat. Commun. 6: 6833.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Turner, D. L.,
    2. K. L. Bickham,
    3. J. J. Thome,
    4. C. Y. Kim,
    5. F. D’Ovidio,
    6. E. J. Wherry,
    7. D. L. Farber
    . 2014. Lung niches for the generation and maintenance of tissue-resident memory T cells. Mucosal Immunol. 7: 501–510.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Wu, T.,
    2. Y. Hu,
    3. Y. T. Lee,
    4. K. R. Bouchard,
    5. A. Benechet,
    6. K. Khanna,
    7. L. S. Cauley
    . 2014. Lung-resident memory CD8 T cells (TRM) are indispensable for optimal cross-protection against pulmonary virus infection. J. Leukoc. Biol. 95: 215–224.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Zens, K. D.,
    2. J. K. Chen,
    3. D. L. Farber
    . 2016. Vaccine-generated lung tissue-resident memory T cells provide heterosubtypic protection to influenza infection. JCI Insight DOI: 10.1172/jci.insight.85832.
  22. ↵
    1. Teijaro, J. R.,
    2. D. Turner,
    3. Q. Pham,
    4. E. J. Wherry,
    5. L. Lefrançois,
    6. D. L. Farber
    . 2011. Cutting edge: tissue-retentive lung memory CD4 T cells mediate optimal protection to respiratory virus infection. J. Immunol. 187: 5510–5514.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Teijaro, J. R.,
    2. D. Verhoeven,
    3. C. A. Page,
    4. D. Turner,
    5. D. L. Farber
    . 2010. Memory CD4 T cells direct protective responses to influenza virus in the lungs through helper-independent mechanisms. J. Virol. 84: 9217–9226.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Oslund, K. L.,
    2. N. Baumgarth
    . 2011. Influenza-induced innate immunity: regulators of viral replication, respiratory tract pathology & adaptive immunity. Future Virol. 6: 951–962.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Wu, H.,
    2. V. Haist,
    3. W. Baumgärtner,
    4. K. Schughart
    . 2010. Sustained viral load and late death in Rag2-/- mice after influenza A virus infection. Virol. J. 7: 172.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Kim, T. S.,
    2. T. J. Braciale
    . 2009. Respiratory dendritic cell subsets differ in their capacity to support the induction of virus-specific cytotoxic CD8+ T cell responses. PLoS One 4: e4204.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Kim, T. S.,
    2. M. M. Hufford,
    3. J. Sun,
    4. Y. X. Fu,
    5. T. J. Braciale
    . 2010. Antigen persistence and the control of local T cell memory by migrant respiratory dendritic cells after acute virus infection. J. Exp. Med. 207: 1161–1172.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Ballesteros-Tato, A.,
    2. B. León,
    3. F. E. Lund,
    4. T. D. Randall
    . 2010. Temporal changes in dendritic cell subsets, cross-priming and costimulation via CD70 control CD8(+) T cell responses to influenza. Nat. Immunol. 11: 216–224.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Belz, G. T.,
    2. C. M. Smith,
    3. L. Kleinert,
    4. P. Reading,
    5. A. Brooks,
    6. K. Shortman,
    7. F. R. Carbone,
    8. W. R. Heath
    . 2004. Distinct migrating and nonmigrating dendritic cell populations are involved in MHC class I-restricted antigen presentation after lung infection with virus. Proc. Natl. Acad. Sci. USA 101: 8670–8675.
    OpenUrlAbstract/FREE Full Text
    1. GeurtsvanKessel, C. H.,
    2. M. A. Willart,
    3. L. S. van Rijt,
    4. F. Muskens,
    5. M. Kool,
    6. C. Baas,
    7. K. Thielemans,
    8. C. Bennett,
    9. B. E. Clausen,
    10. H. C. Hoogsteden, et al
    . 2008. Clearance of influenza virus from the lung depends on migratory langerin+CD11b- but not plasmacytoid dendritic cells. J. Exp. Med. 205: 1621–1634.
    OpenUrlAbstract/FREE Full Text
    1. Waithman, J.,
    2. D. Zanker,
    3. K. Xiao,
    4. S. Oveissi,
    5. B. Wylie,
    6. R. Ng,
    7. L. Tögel,
    8. W. Chen
    . 2013. Resident CD8(+) and migratory CD103(+) dendritic cells control CD8 T cell immunity during acute influenza infection. PLoS One 8: e66136.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Bachem, A.,
    2. E. Hartung,
    3. S. Güttler,
    4. A. Mora,
    5. X. Zhou,
    6. A. Hegemann,
    7. M. Plantinga,
    8. E. Mazzini,
    9. P. Stoitzner,
    10. S. Gurka, et al
    . 2012. Expression of XCR1 characterizes the batf3-dependent lineage of dendritic cells capable of antigen cross-presentation. Front. Immunol. 3: 214.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Townsend, A. R.,
    2. J. Rothbard,
    3. F. M. Gotch,
    4. G. Bahadur,
    5. D. Wraith,
    6. A. J. McMichael
    . 1986. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 44: 959–968.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Belz, G. T.,
    2. W. Xie,
    3. P. C. Doherty
    . 2001. Diversity of epitope and cytokine profiles for primary and secondary influenza a virus-specific CD8+ T cell responses. J. Immunol. 166: 4627–4633.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Crowe, S. R.,
    2. S. C. Miller,
    3. D. M. Brown,
    4. P. S. Adams,
    5. R. W. Dutton,
    6. A. G. Harmsen,
    7. F. E. Lund,
    8. T. D. Randall,
    9. S. L. Swain,
    10. D. L. Woodland
    . 2006. Uneven distribution of MHC class II epitopes within the influenza virus. Vaccine 24: 457–467.
    OpenUrlCrossRefPubMed
    1. Nayak, J. L.,
    2. K. A. Richards,
    3. F. A. Chaves,
    4. A. J. Sant
    . 2010. Analyses of the specificity of CD4 T cells during the primary immune response to influenza virus reveals dramatic MHC-linked asymmetries in reactivity to individual viral proteins. Viral Immunol. 23: 169–180.
    OpenUrlCrossRefPubMed
    1. Babon, J. A.,
    2. J. Cruz,
    3. L. Orphin,
    4. P. Pazoles,
    5. M. D. Co,
    6. F. A. Ennis,
    7. M. Terajima
    . 2009. Genome-wide screening of human T-cell epitopes in influenza A virus reveals a broad spectrum of CD4(+) T-cell responses to internal proteins, hemagglutinins, and neuraminidases. Hum. Immunol. 70: 711–721.
    OpenUrlCrossRefPubMed
    1. Chen, L.,
    2. D. Zanker,
    3. K. Xiao,
    4. C. Wu,
    5. Q. Zou,
    6. W. Chen
    . 2014. Immunodominant CD4+ T-cell responses to influenza A virus in healthy individuals focus on matrix 1 and nucleoprotein. J. Virol. 88: 11760–11773.
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. Assarsson, E.,
    2. H. H. Bui,
    3. J. Sidney,
    4. Q. Zhang,
    5. J. Glenn,
    6. C. Oseroff,
    7. I. N. Mbawuike,
    8. J. Alexander,
    9. M. J. Newman,
    10. H. Grey,
    11. A. Sette
    . 2008. Immunomic analysis of the repertoire of T-cell specificities for influenza A virus in humans. J. Virol. 82: 12241–12251.
    OpenUrlAbstract/FREE Full Text
    1. Grant, E.,
    2. C. Wu,
    3. K. F. Chan,
    4. S. Eckle,
    5. M. Bharadwaj,
    6. Q. M. Zou,
    7. K. Kedzierska,
    8. W. Chen
    . 2013. Nucleoprotein of influenza A virus is a major target of immunodominant CD8+ T-cell responses. Immunol. Cell Biol. 91: 184–194.
    OpenUrlCrossRef
    1. Wu, C.,
    2. D. Zanker,
    3. S. Valkenburg,
    4. B. Tan,
    5. K. Kedzierska,
    6. Q. M. Zou,
    7. P. C. Doherty,
    8. W. Chen
    . 2011. Systematic identification of immunodominant CD8+ T-cell responses to influenza A virus in HLA-A2 individuals. Proc. Natl. Acad. Sci. USA 108: 9178–9183.
    OpenUrlAbstract/FREE Full Text
  42. ↵
    1. Quiñones-Parra, S.,
    2. E. Grant,
    3. L. Loh,
    4. T. H. Nguyen,
    5. K. A. Campbell,
    6. S. Y. Tong,
    7. A. Miller,
    8. P. C. Doherty,
    9. D. Vijaykrishna,
    10. J. Rossjohn, et al
    . 2014. Preexisting CD8+ T-cell immunity to the H7N9 influenza A virus varies across ethnicities. Proc. Natl. Acad. Sci. USA 111: 1049–1054.
    OpenUrlAbstract/FREE Full Text
  43. ↵
    1. Mikhak, Z.,
    2. J. P. Strassner,
    3. A. D. Luster
    . 2013. Lung dendritic cells imprint T cell lung homing and promote lung immunity through the chemokine receptor CCR4. J. Exp. Med. 210: 1855–1869.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    1. Julkunen, I.,
    2. K. Melén,
    3. M. Nyqvist,
    4. J. Pirhonen,
    5. T. Sareneva,
    6. S. Matikainen
    . 2000. Inflammatory responses in influenza A virus infection. Vaccine 19(Suppl 1): S32–S37.
    OpenUrlCrossRefPubMed
  45. ↵
    1. Lim, K.,
    2. Y. M. Hyun,
    3. K. Lambert-Emo,
    4. T. Capece,
    5. S. Bae,
    6. R. Miller,
    7. D. J. Topham,
    8. M. Kim
    . 2015. Neutrophil trails guide influenza-specific CD8+ T cells in the airways. Science 349: aaa4352.
    OpenUrlAbstract/FREE Full Text
  46. ↵
    1. McGill, J.,
    2. N. Van Rooijen,
    3. K. L. Legge
    . 2008. Protective influenza-specific CD8 T cell responses require interactions with dendritic cells in the lungs. J. Exp. Med. 205: 1635–1646.
    OpenUrlAbstract/FREE Full Text
  47. ↵
    1. Hufford, M. M.,
    2. T. S. Kim,
    3. J. Sun,
    4. T. J. Braciale
    . 2011. Antiviral CD8+ T cell effector activities in situ are regulated by target cell type. J. Exp. Med. 208: 167–180.
    OpenUrlAbstract/FREE Full Text
  48. ↵
    1. Kohlmeier, J. E.,
    2. W. W. Reiley,
    3. G. Perona-Wright,
    4. M. L. Freeman,
    5. E. J. Yager,
    6. L. M. Connor,
    7. E. L. Brincks,
    8. T. Cookenham,
    9. A. D. Roberts,
    10. C. E. Burkum, et al
    . 2011. Inflammatory chemokine receptors regulate CD8(+) T cell contraction and memory generation following infection. J. Exp. Med. 208: 1621–1634.
    OpenUrlAbstract/FREE Full Text
  49. ↵
    1. Brown, D. M.,
    2. S. Lee,
    3. M. L. Garcia-Hernandez,
    4. S. L. Swain
    . 2012. Multifunctional CD4 cells expressing gamma interferon and perforin mediate protection against lethal influenza virus infection. J. Virol. 86: 6792–6803.
    OpenUrlAbstract/FREE Full Text
  50. ↵
    1. Sun, J.,
    2. R. Madan,
    3. C. L. Karp,
    4. T. J. Braciale
    . 2009. Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10. Nat. Med. 15: 277–284.
    OpenUrlCrossRefPubMed
  51. ↵
    1. McKinstry, K. K.,
    2. T. M. Strutt,
    3. A. Buck,
    4. J. D. Curtis,
    5. J. P. Dibble,
    6. G. Huston,
    7. M. Tighe,
    8. H. Hamada,
    9. S. Sell,
    10. R. W. Dutton,
    11. S. L. Swain
    . 2009. IL-10 deficiency unleashes an influenza-specific Th17 response and enhances survival against high-dose challenge. J. Immunol. 182: 7353–7363.
    OpenUrlAbstract/FREE Full Text
  52. ↵
    1. Keck, S.,
    2. M. Schmaler,
    3. S. Ganter,
    4. L. Wyss,
    5. S. Oberle,
    6. E. S. Huseby,
    7. D. Zehn,
    8. C. G. King
    . 2014. Antigen affinity and antigen dose exert distinct influences on CD4 T-cell differentiation. Proc. Natl. Acad. Sci. USA 111: 14852–14857.
    OpenUrlAbstract/FREE Full Text
  53. ↵
    1. Krishnamoorthy, V.,
    2. S. Kannanganat,
    3. M. Maienschein-Cline,
    4. S. L. Cook,
    5. J. Chen,
    6. N. Bahroos,
    7. E. Sievert,
    8. E. Corse,
    9. A. Chong,
    10. R. Sciammas
    . 2017. The IRF4 gene regulatory module functions as a read-write integrator to dynamically coordinate T helper cell fate. Immunity 47: 481–497.e7.
    OpenUrl
  54. ↵
    1. Brown, D. M.,
    2. A. M. Dilzer,
    3. D. L. Meents,
    4. S. L. Swain
    . 2006. CD4 T cell-mediated protection from lethal influenza: perforin and antibody-mediated mechanisms give a one-two punch. J. Immunol. 177: 2888–2898.
    OpenUrlAbstract/FREE Full Text
  55. ↵
    1. Marshall, N. B.,
    2. A. M. Vong,
    3. P. Devarajan,
    4. M. D. Brauner,
    5. Y. Kuang,
    6. R. Nayar,
    7. E. A. Schutten,
    8. C. H. Castonguay,
    9. L. J. Berg,
    10. S. L. Nutt,
    11. S. L. Swain
    . 2017. NKG2C/E marks the unique cytotoxic CD4 T cell subset, ThCTL, generated by influenza infection. J. Immunol. 198: 1142–1155.
    OpenUrlAbstract/FREE Full Text
  56. ↵
    1. Takeuchi, A.,
    2. M. S. Badr,
    3. K. Miyauchi,
    4. C. Ishihara,
    5. R. Onishi,
    6. Z. Guo,
    7. Y. Sasaki,
    8. H. Ike,
    9. A. Takumi,
    10. N. M. Tsuji, et al
    . 2016. CRTAM determines the CD4+ cytotoxic T lymphocyte lineage. J. Exp. Med. 213: 123–138.
    OpenUrlAbstract/FREE Full Text
  57. ↵
    1. Cerwenka, A.,
    2. T. M. Morgan,
    3. A. G. Harmsen,
    4. R. W. Dutton
    . 1999. Migration kinetics and final destination of type 1 and type 2 CD8 effector cells predict protection against pulmonary virus infection. J. Exp. Med. 189: 423–434.
    OpenUrlAbstract/FREE Full Text
  58. ↵
    1. Hamada, H.,
    2. M. L. Garcia-Hernandez,
    3. J. B. Reome,
    4. S. K. Misra,
    5. T. M. Strutt,
    6. K. K. McKinstry,
    7. A. M. Cooper,
    8. S. L. Swain,
    9. R. W. Dutton
    . 2009. Tc17, a unique subset of CD8 T cells that can protect against lethal influenza challenge. J. Immunol. 182: 3469–3481.
    OpenUrlAbstract/FREE Full Text
  59. ↵
    1. Hamada, H.,
    2. E. Bassity,
    3. A. Flies,
    4. T. M. Strutt,
    5. M. L. Garcia-Hernandez,
    6. K. K. McKinstry,
    7. T. Zou,
    8. S. L. Swain,
    9. R. W. Dutton
    . 2013. Multiple redundant effector mechanisms of CD8+ T cells protect against influenza infection. J. Immunol. 190: 296–306.
    OpenUrlAbstract/FREE Full Text
  60. ↵
    1. Cullen, S. P.,
    2. S. J. Martin
    . 2008. Mechanisms of granule-dependent killing. Cell Death Differ. 15: 251–262.
    OpenUrlCrossRefPubMed
  61. ↵
    1. Topham, D. J.,
    2. R. A. Tripp,
    3. P. C. Doherty
    . 1997. CD8+ T cells clear influenza virus by perforin or Fas-dependent processes. J. Immunol. 159: 5197–5200.
    OpenUrlAbstract
  62. ↵
    1. Brincks, E. L.,
    2. A. Katewa,
    3. T. A. Kucaba,
    4. T. S. Griffith,
    5. K. L. Legge
    . 2008. CD8 T cells utilize TRAIL to control influenza virus infection. J. Immunol. 181: 4918–4925.
    OpenUrlAbstract/FREE Full Text
  63. ↵
    1. Faroudi, M.,
    2. C. Utzny,
    3. M. Salio,
    4. V. Cerundolo,
    5. M. Guiraud,
    6. S. Müller,
    7. S. Valitutti
    . 2003. Lytic versus stimulatory synapse in cytotoxic T lymphocyte/target cell interaction: manifestation of a dual activation threshold. Proc. Natl. Acad. Sci. USA 100: 14145–14150.
    OpenUrlAbstract/FREE Full Text
    1. Purbhoo, M. A.,
    2. D. J. Irvine,
    3. J. B. Huppa,
    4. M. M. Davis
    . 2004. T cell killing does not require the formation of a stable mature immunological synapse. [Published erratum appears in 2004 Nat. Immunol. 5: 658.] Nat. Immunol. 5: 524–530.
    OpenUrlCrossRefPubMed
  65. ↵
    1. Valitutti, S.,
    2. S. Müller,
    3. M. Dessing,
    4. A. Lanzavecchia
    . 1996. Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J. Exp. Med. 183: 1917–1921.
    OpenUrlAbstract/FREE Full Text
  66. ↵
    1. Obar, J. J.,
    2. L. Lefrançois
    . 2010. Early events governing memory CD8+ T-cell differentiation. Int. Immunol. 22: 619–625.
    OpenUrlCrossRefPubMed
  67. ↵
    1. Kaech, S. M.,
    2. J. T. Tan,
    3. E. J. Wherry,
    4. B. T. Konieczny,
    5. C. D. Surh,
    6. R. Ahmed
    . 2003. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat. Immunol. 4: 1191–1198.
    OpenUrlCrossRefPubMed
  68. ↵
    1. Mueller, S. N.,
    2. L. K. Mackay
    . 2016. Tissue-resident memory T cells: local specialists in immune defence. Nat. Rev. Immunol. 16: 79–89.
    OpenUrlCrossRefPubMed
  69. ↵
    1. Chang, J. T.,
    2. E. J. Wherry,
    3. A. W. Goldrath
    . 2014. Molecular regulation of effector and memory T cell differentiation. Nat. Immunol. 15: 1104–1115.
    OpenUrlCrossRefPubMed
  70. ↵
    1. Condotta, S. A.,
    2. M. J. Richer
    . 2017. The immune battlefield: the impact of inflammatory cytokines on CD8+ T-cell immunity. PLoS Pathog. 13: e1006618.
    OpenUrl
  71. ↵
    1. Billiau, A.,
    2. P. Matthys
    . 2009. Interferon-gamma: a historical perspective. Cytokine Growth Factor Rev. 20: 97–113.
    OpenUrlCrossRefPubMed
  72. ↵
    1. Prabhu, N.,
    2. A. W. Ho,
    3. K. H. Wong,
    4. P. E. Hutchinson,
    5. Y. L. Chua,
    6. M. Kandasamy,
    7. D. C. Lee,
    8. B. Sivasankar,
    9. D. M. Kemeny
    . 2013. Gamma interferon regulates contraction of the influenza virus-specific CD8 T cell response and limits the size of the memory population. J. Virol. 87: 12510–12522.
    OpenUrlAbstract/FREE Full Text
  73. ↵
    1. Shane, H. L.,
    2. K. D. Klonowski
    . 2014. Every breath you take: the impact of environment on resident memory CD8 T cells in the lung. Front. Immunol. 5: 320.
    OpenUrlCrossRef
  74. ↵
    1. Jelley-Gibbs, D. M.,
    2. D. M. Brown,
    3. J. P. Dibble,
    4. L. Haynes,
    5. S. M. Eaton,
    6. S. L. Swain
    . 2005. Unexpected prolonged presentation of influenza antigens promotes CD4 T cell memory generation. J. Exp. Med. 202: 697–706.
    OpenUrlAbstract/FREE Full Text
  75. ↵
    1. McGill, J.,
    2. N. Van Rooijen,
    3. K. L. Legge
    . 2010. IL-15 trans-presentation by pulmonary dendritic cells promotes effector CD8 T cell survival during influenza virus infection. J. Exp. Med. 207: 521–534.
    OpenUrlAbstract/FREE Full Text
  76. ↵
    1. McKinstry, K. K.,
    2. T. M. Strutt,
    3. B. Bautista,
    4. W. Zhang,
    5. Y. Kuang,
    6. A. M. Cooper,
    7. S. L. Swain
    . 2014. Effector CD4 T-cell transition to memory requires late cognate interactions that induce autocrine IL-2. Nat. Commun. 5: 5377.
    OpenUrlCrossRefPubMed
  77. ↵
    1. Hendriks, J.,
    2. L. A. Gravestein,
    3. K. Tesselaar,
    4. R. A. van Lier,
    5. T. N. Schumacher,
    6. J. Borst
    . 2000. CD27 is required for generation and long-term maintenance of T cell immunity. Nat. Immunol. 1: 433–440.
    OpenUrlCrossRefPubMed
  78. ↵
    1. Hendriks, J.,
    2. Y. Xiao,
    3. J. W. Rossen,
    4. K. F. van der Sluijs,
    5. K. Sugamura,
    6. N. Ishii,
    7. J. Borst
    . 2005. During viral infection of the respiratory tract, CD27, 4-1BB, and OX40 collectively determine formation of CD8+ memory T cells and their capacity for secondary expansion. J. Immunol. 175: 1665–1676.
    OpenUrlAbstract/FREE Full Text
  79. ↵
    1. Becker, T. C.,
    2. E. J. Wherry,
    3. D. Boone,
    4. K. Murali-Krishna,
    5. R. Antia,
    6. A. Ma,
    7. R. Ahmed
    . 2002. Interleukin 15 is required for proliferative renewal of virus-specific memory CD8 T cells. J. Exp. Med. 195: 1541–1548.
    OpenUrlAbstract/FREE Full Text
    1. Li, J.,
    2. G. Huston,
    3. S. L. Swain
    . 2003. IL-7 promotes the transition of CD4 effectors to persistent memory cells. J. Exp. Med. 198: 1807–1815.
    OpenUrlAbstract/FREE Full Text
    1. Kondrack, R. M.,
    2. J. Harbertson,
    3. J. T. Tan,
    4. M. E. McBreen,
    5. C. D. Surh,
    6. L. M. Bradley
    . 2003. Interleukin 7 regulates the survival and generation of memory CD4 cells. J. Exp. Med. 198: 1797–1806.
    OpenUrlAbstract/FREE Full Text
  82. ↵
    1. Lenz, D. C.,
    2. S. K. Kurz,
    3. E. Lemmens,
    4. S. P. Schoenberger,
    5. J. Sprent,
    6. M. B. Oldstone,
    7. D. Homann
    . 2004. IL-7 regulates basal homeostatic proliferation of antiviral CD4+T cell memory. Proc. Natl. Acad. Sci. USA 101: 9357–9362.
    OpenUrlAbstract/FREE Full Text
  83. ↵
    1. Cui, G.,
    2. M. M. Staron,
    3. S. M. Gray,
    4. P. C. Ho,
    5. R. A. Amezquita,
    6. J. Wu,
    7. S. M. Kaech
    . 2015. IL-7-Induced glycerol transport and TAG synthesis promotes memory CD8+ T cell longevity. Cell 161: 750–761.
    OpenUrlCrossRefPubMed
  84. ↵
    1. van der Windt, G. J.,
    2. B. Everts,
    3. C. H. Chang,
    4. J. D. Curtis,
    5. T. C. Freitas,
    6. E. Amiel,
    7. E. J. Pearce,
    8. E. L. Pearce
    . 2012. Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development. Immunity 36: 68–78.
    OpenUrlCrossRefPubMed
  85. ↵
    1. Hogan, R. J.,
    2. W. Zhong,
    3. E. J. Usherwood,
    4. T. Cookenham,
    5. A. D. Roberts,
    6. D. L. Woodland
    . 2001. Protection from respiratory virus infections can be mediated by antigen-specific CD4(+) T cells that persist in the lungs. J. Exp. Med. 193: 981–986.
    OpenUrlAbstract/FREE Full Text
  86. ↵
    1. Duan, S.,
    2. V. A. Meliopoulos,
    3. J. L. McClaren,
    4. X. Z. Guo,
    5. C. J. Sanders,
    6. H. S. Smallwood,
    7. R. J. Webby,
    8. S. L. Schultz-Cherry,
    9. P. C. Doherty,
    10. P. G. Thomas
    . 2015. Diverse heterologous primary infections radically alter immunodominance hierarchies and clinical outcomes following H7N9 influenza challenge in mice. PLoS Pathog. 11: e1004642.
    OpenUrlCrossRef
  87. ↵
    1. Duan, S.,
    2. P. G. Thomas
    . 2016. Balancing immune protection and immune pathology by CD8(+) T-cell responses to influenza infection. Front. Immunol. 7: 25.
    OpenUrlCrossRef
  88. ↵
    1. Sallusto, F.,
    2. D. Lenig,
    3. R. Förster,
    4. M. Lipp,
    5. A. Lanzavecchia
    . 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401: 708–712.
    OpenUrlCrossRefPubMed
    1. Farber, D. L.,
    2. M. Ahmadzadeh
    . 2002. Dissecting the complexity of the memory T cell response. Immunol. Res. 25: 247–259.
    OpenUrlCrossRefPubMed
  90. ↵
    1. Bingaman, A. W.,
    2. D. S. Patke,
    3. V. R. Mane,
    4. M. Ahmadzadeh,
    5. M. Ndejembi,
    6. S. T. Bartlett,
    7. D. L. Farber
    . 2005. Novel phenotypes and migratory properties distinguish memory CD4 T cell subsets in lymphoid and lung tissue. Eur. J. Immunol. 35: 3173–3186.
    OpenUrlCrossRefPubMed
  91. ↵
    1. Gebhardt, T.,
    2. L. M. Wakim,
    3. L. Eidsmo,
    4. P. C. Reading,
    5. W. R. Heath,
    6. F. R. Carbone
    . 2009. Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. Nat. Immunol. 10: 524–530.
    OpenUrlCrossRefPubMed
  92. ↵
    1. Kohlmeier, J. E.,
    2. S. C. Miller,
    3. J. Smith,
    4. B. Lu,
    5. C. Gerard,
    6. T. Cookenham,
    7. A. D. Roberts,
    8. D. L. Woodland
    . 2008. The chemokine receptor CCR5 plays a key role in the early memory CD8+ T cell response to respiratory virus infections. Immunity 29: 101–113.
    OpenUrlCrossRefPubMed
  93. ↵
    1. Ray, S. J.,
    2. S. N. Franki,
    3. R. H. Pierce,
    4. S. Dimitrova,
    5. V. Koteliansky,
    6. A. G. Sprague,
    7. P. C. Doherty,
    8. A. R. de Fougerolles,
    9. D. J. Topham
    . 2004. The collagen binding alpha1beta1 integrin VLA-1 regulates CD8 T cell-mediated immune protection against heterologous influenza infection. Immunity 20: 167–179.
    OpenUrlCrossRefPubMed
  94. ↵
    1. Wiley, J. A.,
    2. R. J. Hogan,
    3. D. L. Woodland,
    4. A. G. Harmsen
    . 2001. Antigen-specific CD8(+) T cells persist in the upper respiratory tract following influenza virus infection. J. Immunol. 167: 3293–3299.
    OpenUrlAbstract/FREE Full Text
  95. ↵
    1. Slütter, B.,
    2. L. L. Pewe,
    3. S. M. Kaech,
    4. J. T. Harty
    . 2013. Lung airway-surveilling CXCR3(hi) memory CD8(+) T cells are critical for protection against influenza A virus. Immunity 39: 939–948.
    OpenUrlCrossRefPubMed
  96. ↵
    1. Slütter, B.,
    2. N. Van Braeckel-Budimir,
    3. G. Abboud,
    4. S. M. Varga,
    5. S. Salek-Ardakani,
    6. J. T. Harty
    . 2017. Dynamics of influenza-induced lung-resident memory T cells underlie waning heterosubtypic immunity. Sci. Immunol. DOI: 10.1126/sciimmunol.aag2031.
  97. ↵
    1. Ely, K. H.,
    2. T. Cookenham,
    3. A. D. Roberts,
    4. D. L. Woodland
    . 2006. Memory T cell populations in the lung airways are maintained by continual recruitment. J. Immunol. 176: 537–543.
    OpenUrlAbstract/FREE Full Text
  98. ↵
    1. Takamura, S.,
    2. H. Yagi,
    3. Y. Hakata,
    4. C. Motozono,
    5. S. R. McMaster,
    6. T. Masumoto,
    7. M. Fujisawa,
    8. T. Chikaishi,
    9. J. Komeda,
    10. J. Itoh, et al
    . 2016. Specific niches for lung-resident memory CD8+ T cells at the site of tissue regeneration enable CD69-independent maintenance. J. Exp. Med. 213: 3057–3073.
    OpenUrlAbstract/FREE Full Text
  99. ↵
    1. Yoshizawa, A.,
    2. K. Bi,
    3. D. B. Keskin,
    4. G. Zhang,
    5. B. Reinhold,
    6. E. L. Reinherz
    . 2018. TCR-pMHC encounter differentially regulates transcriptomes of tissue-resident CD8 T cells. Eur. J. Immunol. 48: 128–150.
    OpenUrl
  100. ↵
    1. Roberts, A. I.,
    2. R. E. Brolin,
    3. E. C. Ebert
    . 1999. Integrin alpha1beta1 (VLA-1) mediates adhesion of activated intraepithelial lymphocytes to collagen. Immunology 97: 679–685.
    OpenUrlCrossRefPubMed
  101. ↵
    1. Shiow, L. R.,
    2. D. B. Rosen,
    3. N. Brdicková,
    4. Y. Xu,
    5. J. An,
    6. L. L. Lanier,
    7. J. G. Cyster,
    8. M. Matloubian
    . 2006. CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature 440: 540–544.
    OpenUrlCrossRefPubMed
  102. ↵
    1. Lee, Y. T.,
    2. J. E. Suarez-Ramirez,
    3. T. Wu,
    4. J. M. Redman,
    5. K. Bouchard,
    6. G. A. Hadley,
    7. L. S. Cauley
    . 2011. Environmental and antigen receptor-derived signals support sustained surveillance of the lungs by pathogen-specific cytotoxic T lymphocytes. J. Virol. 85: 4085–4094.
    OpenUrlAbstract/FREE Full Text
  103. ↵
    1. Hadley, G. A.,
    2. S. T. Bartlett,
    3. C. S. Via,
    4. E. A. Rostapshova,
    5. S. Moainie
    . 1997. The epithelial cell-specific integrin, CD103 (alpha E integrin), defines a novel subset of alloreactive CD8+ CTL. J. Immunol. 159: 3748–3756.
    OpenUrlAbstract
  104. ↵
    1. Cepek, K. L.,
    2. S. K. Shaw,
    3. C. M. Parker,
    4. G. J. Russell,
    5. J. S. Morrow,
    6. D. L. Rimm,
    7. M. B. Brenner
    . 1994. Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the alpha E beta 7 integrin. Nature 372: 190–193.
    OpenUrlCrossRefPubMed
  105. ↵
    1. Purwar, R.,
    2. J. Campbell,
    3. G. Murphy,
    4. W. G. Richards,
    5. R. A. Clark,
    6. T. S. Kupper
    . 2011. Resident memory T cells (T(RM)) are abundant in human lung: diversity, function, and antigen specificity. PLoS One 6: e16245.
    OpenUrlCrossRefPubMed
    1. Piet, B.,
    2. G. J. de Bree,
    3. B. S. Smids-Dierdorp,
    4. C. M. van der Loos,
    5. E. B. Remmerswaal,
    6. J. H. von der Thüsen,
    7. J. M. van Haarst,
    8. J. P. Eerenberg,
    9. A. ten Brinke,
    10. W. van der Bij, et al
    . 2011. CD8+ T cells with an intraepithelial phenotype upregulate cytotoxic function upon influenza infection in human lung. J. Clin. Invest. 121: 2254–2263.
    OpenUrlCrossRefPubMed
  107. ↵
    1. Pizzolla, A.,
    2. T. H. Nguyen,
    3. S. Sant,
    4. J. Jaffar,
    5. T. Loudovaris,
    6. S. I. Mannering,
    7. P. G. Thomas,
    8. G. P. Westall,
    9. K. Kedzierska,
    10. L. M. Wakim
    . 2018. Influenza-specific lung-resident memory T cells are proliferative and polyfunctional and maintain diverse TCR profiles. J. Clin. Invest. 128: 721–733.
    OpenUrl
  108. ↵
    1. Oja, A. E.,
    2. B. Piet,
    3. C. Helbig,
    4. R. Stark,
    5. D. van der Zwan,
    6. H. Blaauwgeers,
    7. E. B. M. Remmerswaal,
    8. D. Amsen,
    9. R. E. Jonkers,
    10. P. D. Moerland, et al
    . 2018. Trigger-happy resident memory CD4(+) T cells inhabit the human lungs. Mucosal Immunol. 11: 654–667.
    OpenUrl
  109. ↵
    1. Hombrink, P.,
    2. C. Helbig,
    3. R. A. Backer,
    4. B. Piet,
    5. A. E. Oja,
    6. R. Stark,
    7. G. Brasser,
    8. A. Jongejan,
    9. R. E. Jonkers,
    10. B. Nota, et al
    . 2016. Programs for the persistence, vigilance and control of human CD8+ lung-resident memory T cells. Nat. Immunol. 17: 1467–1478.
    OpenUrlCrossRef
  110. ↵
    1. Takamura, S.,
    2. A. D. Roberts,
    3. D. M. Jelley-Gibbs,
    4. S. T. Wittmer,
    5. J. E. Kohlmeier,
    6. D. L. Woodland
    . 2010. The route of priming influences the ability of respiratory virus-specific memory CD8+ T cells to be activated by residual antigen. J. Exp. Med. 207: 1153–1160.
    OpenUrlAbstract/FREE Full Text
  111. ↵
    1. Laidlaw, B. J.,
    2. N. Zhang,
    3. H. D. Marshall,
    4. M. M. Staron,
    5. T. Guan,
    6. Y. Hu,
    7. L. S. Cauley,
    8. J. Craft,
    9. S. M. Kaech
    . 2014. CD4+ T cell help guides formation of CD103+ lung-resident memory CD8+ T cells during influenza viral infection. Immunity 41: 633–645.
    OpenUrlCrossRefPubMed
  112. ↵
    1. Mackay, L. K.,
    2. E. Wynne-Jones,
    3. D. Freestone,
    4. D. G. Pellicci,
    5. L. A. Mielke,
    6. D. M. Newman,
    7. A. Braun,
    8. F. Masson,
    9. A. Kallies,
    10. G. T. Belz,
    11. F. R. Carbone
    . 2015. T-box transcription factors combine with the cytokines TGF-β and IL-15 to control tissue-resident memory T cell fate. Immunity 43: 1101–1111.
    OpenUrlCrossRefPubMed
  113. ↵
    1. Wakim, L. M.,
    2. N. Gupta,
    3. J. D. Mintern,
    4. J. A. Villadangos
    . 2013. Enhanced survival of lung tissue-resident memory CD8+ T cells during infection with influenza virus due to selective expression of IFITM3. Nat. Immunol. 14: 238–245.
    OpenUrlCrossRefPubMed
  114. ↵
    1. Mackay, L. K.,
    2. A. Rahimpour,
    3. J. Z. Ma,
    4. N. Collins,
    5. A. T. Stock,
    6. M. L. Hafon,
    7. J. Vega-Ramos,
    8. P. Lauzurica,
    9. S. N. Mueller,
    10. T. Stefanovic, et al
    . 2013. The developmental pathway for CD103(+)CD8+ tissue-resident memory T cells of skin. Nat. Immunol. 14: 1294–1301.
    OpenUrlCrossRefPubMed
  115. ↵
    1. Skon, C. N.,
    2. J. Y. Lee,
    3. K. G. Anderson,
    4. D. Masopust,
    5. K. A. Hogquist,
    6. S. C. Jameson
    . 2013. Transcriptional downregulation of S1pr1 is required for the establishment of resident memory CD8+ T cells. Nat. Immunol. 14: 1285–1293.
    OpenUrlCrossRefPubMed
  116. ↵
    1. Milner, J. J.,
    2. C. Toma,
    3. B. Yu,
    4. K. Zhang,
    5. K. Omilusik,
    6. A. T. Phan,
    7. D. Wang,
    8. A. J. Getzler,
    9. T. Nguyen,
    10. S. Crotty, et al
    . 2017. Runx3 programs CD8+ T cell residency in non-lymphoid tissues and tumours. Nature 552: 253–257.
    OpenUrlCrossRef
  117. ↵
    1. Mackay, L. K.,
    2. M. Minnich,
    3. N. A. Kragten,
    4. Y. Liao,
    5. B. Nota,
    6. C. Seillet,
    7. A. Zaid,
    8. K. Man,
    9. S. Preston,
    10. D. Freestone, et al
    . 2016. Hobit and Blimp1 instruct a universal transcriptional program of tissue residency in lymphocytes. Science 352: 459–463.
    OpenUrlAbstract/FREE Full Text
  118. ↵
    1. Kumar, B. V.,
    2. W. Ma,
    3. M. Miron,
    4. T. Granot,
    5. R. S. Guyer,
    6. D. J. Carpenter,
    7. T. Senda,
    8. X. Sun,
    9. S. H. Ho,
    10. H. Lerner, et al
    . 2017. Human tissue-resident memory T cells are defined by core transcriptional and functional signatures in lymphoid and mucosal sites. Cell Rep. 20: 2921–2934.
    OpenUrl
  119. ↵
    1. Wakim, L. M.,
    2. J. Smith,
    3. I. Caminschi,
    4. M. H. Lahoud,
    5. J. A. Villadangos
    . 2015. Antibody-targeted vaccination to lung dendritic cells generates tissue-resident memory CD8 T cells that are highly protective against influenza virus infection. Mucosal Immunol. 8: 1060–1071.
    OpenUrlCrossRefPubMed
  120. ↵
    1. Mackay, L. K.,
    2. A. T. Stock,
    3. J. Z. Ma,
    4. C. M. Jones,
    5. S. J. Kent,
    6. S. N. Mueller,
    7. W. R. Heath,
    8. F. R. Carbone,
    9. T. Gebhardt
    . 2012. Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation. Proc. Natl. Acad. Sci. USA 109: 7037–7042.
    OpenUrlAbstract/FREE Full Text
  121. ↵
    1. Bergsbaken, T.,
    2. M. J. Bevan
    . 2015. Proinflammatory microenvironments within the intestine regulate the differentiation of tissue-resident CD8+ T cells responding to infection. Nat. Immunol. 16: 406–414.
    OpenUrlCrossRefPubMed
  122. ↵
    1. Sheridan, B. S.,
    2. Q. M. Pham,
    3. Y. T. Lee,
    4. L. S. Cauley,
    5. L. Puddington,
    6. L. Lefrançois
    . 2014. Oral infection drives a distinct population of intestinal resident memory CD8(+) T cells with enhanced protective function. Immunity 40: 747–757.
    OpenUrlCrossRefPubMed
  123. ↵
    1. Kedzierska, K.,
    2. V. Venturi,
    3. K. Field,
    4. M. P. Davenport,
    5. S. J. Turner,
    6. P. C. Doherty
    . 2006. Early establishment of diverse T cell receptor profiles for influenza-specific CD8(+)CD62L(hi) memory T cells. Proc. Natl. Acad. Sci. USA 103: 9184–9189.
    OpenUrlAbstract/FREE Full Text
  124. ↵
    1. Hogan, R. J.,
    2. E. J. Usherwood,
    3. W. Zhong,
    4. A. A. Roberts,
    5. R. W. Dutton,
    6. A. G. Harmsen,
    7. D. L. Woodland
    . 2001. Activated antigen-specific CD8+ T cells persist in the lungs following recovery from respiratory virus infections. J. Immunol. 166: 1813–1822.
    OpenUrlAbstract/FREE Full Text
  125. ↵
    1. Clever, D.,
    2. R. Roychoudhuri,
    3. M. G. Constantinides,
    4. M. H. Askenase,
    5. M. Sukumar,
    6. C. A. Klebanoff,
    7. R. L. Eil,
    8. H. D. Hickman,
    9. Z. Yu,
    10. J. H. Pan, et al
    . 2016. Oxygen sensing by T cells establishes an immunologically tolerant metastatic niche. Cell 166: 1117–1131.e14.
    OpenUrlCrossRef
  126. ↵
    1. Shen, C. H.,
    2. Q. Ge,
    3. O. Talay,
    4. H. N. Eisen,
    5. A. García-Sastre,
    6. J. Chen
    . 2008. Loss of IL-7R and IL-15R expression is associated with disappearance of memory T cells in respiratory tract following influenza infection. J. Immunol. 180: 171–178.
    OpenUrlAbstract/FREE Full Text
  127. ↵
    1. Clemens, E. B.,
    2. C. van de Sandt,
    3. S. S. Wong,
    4. L. M. Wakim,
    5. S. A. Valkenburg
    . 2018. Harnessing the power of T cells: the promising hope for a universal influenza vaccine. Vaccines (Basel) DOI: 10.3390/vaccines6020018.
  128. ↵
    1. Koutsakos, M.,
    2. A. K. Wheatley,
    3. L. Loh,
    4. E. B. Clemens,
    5. S. Sant,
    6. S. Nüssing,
    7. A. Fox,
    8. A. W. Chung,
    9. K. L. Laurie,
    10. A. C. Hurt, et al
    . 2018. Circulating TFH cells, serological memory, and tissue compartmentalization shape human influenza-specific B cell immunity. Sci. Transl. Med. DOI: 10.1126/scitranslmed.aan8405.
  129. ↵
    1. Hoft, D. F.,
    2. E. Babusis,
    3. S. Worku,
    4. C. T. Spencer,
    5. K. Lottenbach,
    6. S. M. Truscott,
    7. G. Abate,
    8. I. G. Sakala,
    9. K. M. Edwards,
    10. C. B. Creech, et al
    . 2011. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J. Infect. Dis. 204: 845–853.
    OpenUrlCrossRefPubMed
  130. ↵
    1. Pleguezuelos, O.,
    2. S. Robinson,
    3. A. Fernández,
    4. G. A. Stoloff,
    5. A. Mann,
    6. A. Gilbert,
    7. G. Balaratnam,
    8. T. Wilkinson,
    9. R. Lambkin-Williams,
    10. J. Oxford,
    11. W. Caparrós-Wanderley
    . 2015. A synthetic influenza virus vaccine induces a cellular immune response that correlates with reduction in symptomatology and virus shedding in a randomized phase ib live-virus challenge in humans. Clin. Vaccine Immunol. 22: 828–835.
    OpenUrlAbstract/FREE Full Text
  131. ↵
    1. Lillie, P. J.,
    2. T. K. Berthoud,
    3. T. J. Powell,
    4. T. Lambe,
    5. C. Mullarkey,
    6. A. J. Spencer,
    7. M. Hamill,
    8. Y. Peng,
    9. M. E. Blais,
    10. C. J. Duncan, et al
    . 2012. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin. Infect. Dis. 55: 19–25.
    OpenUrlCrossRefPubMed
  132. ↵
    1. Francis, J. N.,
    2. C. J. Bunce,
    3. C. Horlock,
    4. J. M. Watson,
    5. S. J. Warrington,
    6. B. Georges,
    7. C. B. Brown
    . 2015. A novel peptide-based pan-influenza A vaccine: a double blind, randomised clinical trial of immunogenicity and safety. Vaccine 33: 396–402.
    OpenUrl
  133. ↵
    1. Deliyannis, G.,
    2. K. Kedzierska,
    3. Y. F. Lau,
    4. W. Zeng,
    5. S. J. Turner,
    6. D. C. Jackson,
    7. L. E. Brown
    . 2006. Intranasal lipopeptide primes lung-resident memory CD8+ T cells for long-term pulmonary protection against influenza. Eur. J. Immunol. 36: 770–778.
    OpenUrlCrossRefPubMed
    1. Gasper, D. J.,
    2. B. Neldner,
    3. E. H. Plisch,
    4. H. Rustom,
    5. E. Carrow,
    6. H. Imai,
    7. Y. Kawaoka,
    8. M. Suresh
    . 2016. Effective respiratory CD8 T-cell immunity to influenza virus induced by intranasal carbomer-lecithin-adjuvanted non-replicating vaccines. PLoS Pathog. 12: e1006064.
    OpenUrl
  135. ↵
    1. Gilchuk, P.,
    2. T. M. Hill,
    3. C. Guy,
    4. S. R. McMaster,
    5. K. L. Boyd,
    6. W. A. Rabacal,
    7. P. Lu,
    8. Y. Shyr,
    9. J. E. Kohlmeier,
    10. E. Sebzda, et al
    . 2016. A distinct lung-interstitium-resident memory CD8(+) T cell subset confers enhanced protection to lower respiratory tract infection. Cell Rep. 16: 1800–1809.
    OpenUrl
  136. ↵
    1. Uddback, I. E.,
    2. L. M. Pedersen,
    3. S. R. Pedersen,
    4. M. A. Steffensen,
    5. P. J. Holst,
    6. A. R. Thomsen,
    7. J. P. Christensen
    . 2016. Combined local and systemic immunization is essential for durable T-cell mediated heterosubtypic immunity against influenza A virus. Sci. Rep. 6: 20137.
    OpenUrlCrossRefPubMed
  137. ↵
    1. Reagin, K. L.,
    2. K. D. Klonowski
    . 2018. Incomplete memories: the natural suppression of tissue-resident memory CD8 T cells in the lung. Front. Immunol. 9: 17.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section